“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
Create an account and get access to all information about Alnylam Pharmaceuticals
No Credit card required. Free Credit
No Credit card required. It’s fast, easy, and FREE! 🛠️
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
About
+1
ALNYLAM IS LEADING THE RNAi REVOLUTIONTM Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics a revolutionary approach to treating diseases which silences the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylams work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the worlds first RNAi therapeutic was approved. Since then, four more Alnylam-developed medicines have been approved and were hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,500+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. Thats why were consistently ranked as a top employer by The Bo...
| C-Level 27 | VP - Level84 |
| Director622 | Manager398 |
| Others863 | |
| Structure | Email Format |
|---|---|
| <f><last>@ |
|
| <first>@ | John@alnylam.com |
| <last>@ | Smith@alnylam.com |
| <first>.<last>@ | John.Smith@alnylam.com |
| Pain Points | Locations | Technologies |
|---|---|---|
| Application Development | Cambridge, MA | revolution, basic, communication, programming language, e, sas, simulation, data analysis, r, data management, hoc, operations |
| Application Development | Germany | revolution, compliance, communication, e |
| Application Development | Turin, Piedmont, Italy | revolution, compliance, communication, collaboration |
| Backup,DR, Dedup | Cambridge, MA | revolution, basic, communication, randomization, programming language, e, sas, simulation, data analysis, r, integrity, data management, collaboration, hoc, operations, python, financial |
| Backup,DR, Dedup | Florence, Tuscany, Italy | revolution, compliance, communication, collaboration |
Alnylam Pharmaceuticals looking to hire in Build & Release in Perugia, Umbria, Italy
Alnylam Pharmaceuticals looking to hire in Build & Release in Turin, Piedmont, Italy
Alnylam Pharmaceuticals looking to hire in Backup,DR, Dedup in United States
Aws
Adobe creative cloud
Amazon connect
Atlassian jira
Cmms
4g
Agile
Cvent
Infrastructure management
Scrum
This role is considered Virtual.OverviewWe are seeking a highly skilled and experienced Principal...
View MoreThis role is considered Hybrid.Associate Director Job DescriptionThe Associate Director in Clinic...
View MoreThis role is considered Hybrid. Principal Statistical Programmer The Principal Statistical Progra...
View MoreThis role is considered Virtual. 1984: Key Account Manager, Rare Diseases Location: Italy Field...
View MoreThis role is considered Virtual.OverviewWe are looking for experienced Business Account Executive...
View MoreOverviewThe Executive Director of DMPK is a senior strategic member of the Early Development Depa...
View MoreThis role is considered Virtual.OverviewAlnylam is seeking to hire an experienced, driven and inn...
View MoreOverviewAs the Senior Manager, Omnichannel Marketing, International, you will play a pivotal role...
View MoreAlnylam Pharmaceuticals has seen its Fair Value Estimate rise from $467.94 to $480.17, reflecting a modestly stronger outlook supported by recent analyst
Read MoreAlnylam stands out in biotech with strong revenue growth, a robust pipeline, and proven commercial success. Read why ALNY stock is a Buy.
Read MoreAlnylam Pharmaceuticals, Inc. v. Moderna, Inc., Appeal No. 2023-2357 (Fed. Cir. June 4, 2025) In this week's Case of the Week, the
Read MoreAlnylam Pharmaceuticals , Inc. (NASDAQ:ALNY), with a substantial market capitalization of $38.2 billion, has been making waves in the biotechnology sector
Read MoreALNYLAM IS LEADING THE RNAi REVOLUTIONTM Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics a revolutionary approach to treating diseases which silences the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylams work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the worlds first RNAi therapeutic was approved. Since then, four more Alnylam-developed medicines have been approved and were hard at work...
Biotech,pharmaceuticals,biopharma,drug development,rare diseases,and rnai
Alnylam pharmaceuticals operates in the Biotechnology research industry.
Alnylam pharmaceuticals's revenue is $2.25b
Alnylam pharmaceuticals has 1001 - 5000 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.